NYSEMKT: PTHS
Pelthos Therapeutics Inc Stock

$7.10+0.26 (+3.8%)
Updated Nov 18, 2026
PTHS Price
$7.10
Fair Value Price
N/A
Market Cap
$27.91M
52 Week Low
$6.02
52 Week High
$31.62
P/E
-0.29x
P/B
-4.51x
P/S
1.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.29M
Earnings
-$78.05M
Gross Margin
83.2%
Operating Margin
-149.43%
Profit Margin
-152.2%
Debt to Equity
-21.82
Operating Cash Flow
-$32M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PTHS's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PTHS
Ranked
#186 of 449

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PTHS news, forecast changes, insider trades & much more!

PTHS News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTHS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PTHS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTHS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PTHS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PTHS due diligence checks available for Premium users.

Valuation

PTHS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.29x
Industry
17.98x
Market
41.36x

PTHS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-4.51x
Industry
4.91x

PTHS's financial health

Profit margin

Revenue
$15.4M
Net Income
-$7.9M
Profit Margin
-51.3%
PTHS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PTHS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$128.8M
Liabilities
$135.0M
Debt to equity
-21.82
PTHS's short-term assets ($56.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTHS's long-term liabilities ($103.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTHS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTHS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.2M
Investing
-$60.0k
Financing
-$1.2M
PTHS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PTHS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PTHSC$27.91M+3.80%-0.29x-4.51x
PMND$28.16M-2.49%-0.48x0.67x
FLNAD$27.40M+13.31%-0.63x0.47x
BCTXD$28.64M-6.55%-0.47x1.84x
NNVCC$30.41M+2.59%-2.25x4.74x

Pelthos Therapeutics Stock FAQ

What is Pelthos Therapeutics's quote symbol?

(NYSEMKT: PTHS) Pelthos Therapeutics trades on the NYSEMKT under the ticker symbol PTHS. Pelthos Therapeutics stock quotes can also be displayed as NYSEMKT: PTHS.

If you're new to stock investing, here's how to buy Pelthos Therapeutics stock.

What is the 52 week high and low for Pelthos Therapeutics (NYSEMKT: PTHS)?

(NYSEMKT: PTHS) Pelthos Therapeutics's 52-week high was $31.62, and its 52-week low was $6.02. It is currently -77.55% from its 52-week high and 17.94% from its 52-week low.

How much is Pelthos Therapeutics stock worth today?

(NYSEMKT: PTHS) Pelthos Therapeutics currently has 3,930,709 outstanding shares. With Pelthos Therapeutics stock trading at $7.10 per share, the total value of Pelthos Therapeutics stock (market capitalization) is $27.91M.

Pelthos Therapeutics stock was originally listed at a price of $48.00 in Feb 16, 2024. If you had invested in Pelthos Therapeutics stock at $48.00, your return over the last 2 years would have been -85.21%, for an annualized return of -61.54% (not including any dividends or dividend reinvestments).

How much is Pelthos Therapeutics's stock price per share?

(NYSEMKT: PTHS) Pelthos Therapeutics stock price per share is $7.10 today (as of Nov 18, 2026).

What is Pelthos Therapeutics's Market Cap?

(NYSEMKT: PTHS) Pelthos Therapeutics's market cap is $27.91M, as of Nov 19, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pelthos Therapeutics's market cap is calculated by multiplying PTHS's current stock price of $7.10 by PTHS's total outstanding shares of 3,930,709.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.